Navigation Links
Vaccine Can Prevent Cervical Cancer and Precancerous Lesions

LONDON, June 28, 2007--A cervical cancer vaccine has shown 90% efficacy for prevention of cervical cancer and precancerous lesions associated with the human papillomavirus (HPV) types targeted by the vaccine, conclude authors of an Article published early Online and in the upcoming issue of The Lancet.

HPV types 16 and 18 account for 70% or more cases of cervical cancer worldwide, but there are up to 15 oncogenic HPV types which can contribute to cervical cancer.

Professor Jorma Paavonen, Department of Obstetrics and Gynaecology, University of Helsinki, Finland, and colleagues randomly assigned 9 258 women to receive the HPV 16/18 vaccine, and 9 267 women in a control group received Hepatitis A vaccine. Women who may have already been infected with HPV were included in the study, as were women who had low-grade cytological abnormalities at study entry.

With an average follow-up of 15 months, the investigators found the vaccine had 90·4% efficacy against high-grade cervical intraepithelial neoplasia (CIN 2/3, a cervical cancer precursor) associated with HPV types 16 and 18. They found also that many CIN lesions contained several oncogenic HPV types. The level of protection against persistent infections with HPV16/18 at 6 and 12 months was 80·4% and 75·9%, respectively. The study extended earlier results of cross-protection against HPV 45 and HPV 31, which cause up to 10% of cases of cervical cancer.

The authors say: "Our results show that the vaccine is effective, well-tolerated and immunogenic in a broad population of young adult women, lending support to its potential value in preventing CIN and cervical cancer."

In an accompanying Comment, Dr Jessica Kahn, Cincinnati Children’s Medical Center, University of Cincinnati College of Medicine, USA, and Dr Robert Burk, Albert Einstein College of Medicine, New York, USA, state: "Althou gh these interim efficacy data are encouraging, their interpretation has limitations. The follow-up was brief, given that cervical carcinogenesis often evolves over several decades. They also highlight increases in adverse reactions among women in the HPV vaccine group.

Finally, the Comment authors raise the issue of ensuring the vaccine is distributed in the developing world, where cervical cancer makes the largest contribution to years of life lost to cancer, concluding: "Poverty is strongly associated with high-risk HPV infection and cervical cancer. If those who live in poverty cannot access a highly effective intervention such as HPV vaccines, disparities could worsen dramatically."

Professor Jorma Paavonen, Department of Obstetrics and Gynaecology, University of Helsinki, Finland. T) +35 8400497900

Comment Dr Jessica Kahn, Cincinnati Children’s Medical Center, University of Cincinnati College of Medicine, USA. T) +1 513 636 8587

Jorma.Paavonen@hus.fi

Jessica.kahn@cchmc.org


pressoffice@lancet.com
Telephone: +44 (0)20 7424 4949/4249
'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
8. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
9. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
10. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017  Pennsylvania Secretary of Health Dr. ... marijuana growers/processors and dispensaries are now available on ... Permit applications will be accepted from February 20 ... an important step forward in getting this valuable ... Murphy said. "We,ve developed a thorough application that ...
(Date:1/17/2017)... 17, 2017  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, plans to ... 31, 2016 after the market closes on Wednesday, February ... 5:00 p.m. ET that day to discuss those results. ... (877) 407-8037 or (201) 689-8037.  For 72 hours following ...
(Date:1/17/2017)... 2017  Market Research Future published a Half Cooked Research Report ... to reach USD 33.6 million during the period 2016 to 2022 ... ... Market has been examined as a swiftly growing market and expected ... for endoscopy device in various regions.  The increasing growth in endoscopy ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... For breast cancer clinicians ... (SABCS) or those who desire a more intimate review and analysis of its highlights, ... Bench to Bedside—is being offered by Imedex on February 4, 2017 in Chicago. Chaired ...
(Date:1/17/2017)... ... 17, 2017 , ... Healthful Balance announces the national release ... operated by Ed Stroup, was created to offer the highest quality vitamins and ... customer service. Healthful Balance products can be purchased online through their website, or ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the ... be featuring DRTV campaigns regarding the topic of Beauty and Personal Care. ... of themselves. What better way to commit to these changes than beginning with personal ...
(Date:1/17/2017)... Florida (PRWEB) , ... January 17, 2017 , ... ... City, a new 21st century approach to infusing high speed technology into the ... area exclusively dedicated to the advancement of healthcare and wellness in a yet-to-be-named, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
Breaking Medicine News(10 mins):